Irinotecan in the treatment of small cell lung cancer: A review of patient safety considerations

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 303-312

  Kawahara, Masaaki ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy; Irinotecan (CPT 11); Radiotherapy; Small cell lung cancer (SCLC); Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANEMIA; AREA UNDER THE CURVE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SAFETY; PNEUMONIA; QUALITY OF LIFE; REVIEW; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; LUNG TUMOR; SMALL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CLINICAL TRIALS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; NEUTROPENIA; PATIENT COMPLIANCE; QUALITY OF LIFE;

EID: 33644891631     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.303     Document Type: Review

References (60)

1. PISANI P, PARKIN DM, BRAY F, FERLAY J: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer (1999) 83:18-29.
2. PAGE N, READ W, TIERNEY R, ARQUETTE M, PICCIRILLO J, GOVINDAN R: The epidemiology of small cell lung canrcinoma. Proc. Am. Soc. Clin. Oncol. (2002) 21:305 (Abstract 1216).
3. STUPP R, MONNERAT C, TURRISI AT, 3rd, PERRY MC, LEYVRAZ S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer (2004) 45(I):105-117.
4. COMIS RL, FRIEDLAND DM, GOOD BC: Small-cell lung cancer: a perspective on the past and a preview of the future. Oncology (1998) 12(1 Suppl 2):44-50.
5. WOLF M, TEBBE S, FINK T: First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer (2004) 45(Suppl. 2):S223-S234.
6. IYER L, KING CD, WHITINGTON PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. (1998) 101(4):847-854.
7. MCLEOD HL: Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics (2004) 5(2):139-141.
8. SPARREBOOM A, DANESI R, ANDO Y, CHAN J, FIGG WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. (2003) 6(2):71-84.
9. MARSH S, MCLEOD HL: Pharmacogenetics of irinotecan toxicity. Pharmacogenomics (2004) 5(7):835-843.
10. MA MK, MCLEOD HL: Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem. (2003) 10(1):41-49.
11. DE JONG FA, DE JONGE MJ, VERWEIJ J, MATHIJSSEN RH: Role of pharmacogenetics in irinotecan therapy. Cancer Lett. (2005) Epub ahead of print.
12. TAKIMOTO CH: Chapter 15: Pharmacology of Cancer Chemotherapy: Section 7: Topoisomerase Interactive Agents. 7th Ed., Philadelphia: Lippincott Williams & Wilkins (2005):375-390.
13. KUHN JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (2002) 16(8 Suppl. 7):33-40.
14. YONEMORI K, TAKEDA Y, TOYOTA E, KOBAYASHI N, KUDO K: Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer. Int. J. Clin. Oncol. (2004) 9(3):206-209.
15. MATHIJSSEN RH, VERWEIJ J, DE BRUIJN P, LOOS WJ, SPARREBOOM A: Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst. (2002) 94(16):1247-1249.
16. KEHRER DF, MATHIJSSEN RH, VERWEIJ J, DE BRUIJN P, SPARREBOOM A: Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. (2002) 20(14):3122-3129.
17. OHE Y: Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer. Panminerva Med. (2002) 44(3):205-212.
18. ABIGERGES D, ARMAND JP, CHABOT GG et al.: Irinotecan (CPT- 11) high-dose escalation using intensive high-dose lopefamide to control diarrhea. J. Natl. Cancer. Inst. (1994) 86(6):446-449.
19. ARMAND JP, TERRET C, COUTEAU C, RIXE O: CPT- 11. The European experience. Ann. N Y Acad. Sci. (1996) 803:282-291.
20. KUDOH S, FUJIWARA Y, TAKADA Y et al.: Phase II study of irinotecan combine with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol. (1998) 16(3):1068-1074.
21. KUBOTA K, NISHIWAKI Y, SUGIURA T et al.: Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin. Cancer Res. (2005) 11(15):5534-5538.
22. VON PAWEL J, SCHILLER JH, SHEPHERD FA et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. (1999) 17(2):658-667.
23. VON PAWEL J: The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer (2003) 41(Suppl. 4):S3-S8.
24. NEGORO S, FUKUOKA M, NIITANI H, TAGUCHI T: Phase II study of CPT-11, new camptothecin derivative, in small cell lng cancer (SCLC) (abstract). Proc. Am. Soc. Clin. Oncol. (1991) 10:214.
25. MASUDA N, FUKUOKA M, KUSUNOKI Y et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. (1992) 10(8):1225-1229.
26. NODA K, NISHIWAKI Y, KAWAHARA M et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. (2002) 346(2):85-91.
27. HANNA NH, EINHORN L, SANDLER A et al.: Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. (2005) 23:622s.
28. TAKIGAWA N, FUJIWARA K, UEOKA H et al.: Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res. (2003) 23(1B):557-560.
29. HAN JY, LEE DH, LEE SY et al.: A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer. Med. Oncol. (2005) 22(3):281-290.
30. SCHMITTEL A, SCHULZE K, HUTTER G, KREBS P, THIEL E, KEILHOLZ U: Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie (2004) 27(3):280-284.
31. FUKUDA M, OKA M, SODA H et al.: Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin. Cancer Res. (1999) 5(12):3963-3969.
32. SCHMITTEL A, FISCHERVON WEIKERSTHAL L, SEBASTIAN M et al.: Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: A randomized phase II trial. Proc. Am. Soc. Clin. Oncol. (2005) 23:632s.
33. KUDOH S, NAKAMURA S, NAKANO T et al.: Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group. Lung Cancer (2005) 49(2):263-269.
34. SEKINE I, NISHIWAKI Y, NODA K et al.: Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann. Oncol. (2003) 14(5):709-714.
35. BRIASOULIS E, SAMANTAS E, KALOFONOS H et al.: Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. Cancer Chemother. Pharmacol. (2005) 56(5):521-528.
36. SAMANTAS E, SYRIGOS K, BRIASOULIS E et al.: Phase II study of cisplatin plus etoposide over 3 days combined with irinotoecan and early thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell lung cancer (SCLC), preliminary results. Lung Cancer (2005) 49(Supl. 2):S327.
37. THOMPSON DS, HAINSWORTH JD, SPIGEL DR et al.: Irinotecan (I), carboplatin (C), and imatinib (IM) in the first-line treatment of extensive-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2005) 23:632s.
38. HUISMAN C, POSTMUS PE, GIACCONE G, SMIT EF: Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat. Rev. (1999) 25(4):199-206.
39. ANDO M, KOBAYASHI K, YOSHIMURA A et al.: Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer (2004) 44(1):121-127.
40. NAKA N, KAWAHARA M, OKISHIO K et al.: Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer (2002) 37(3):319-323.
41. HIROSE T, HORICHI N, OHMORI T et al.: Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer (2003) 40(3):333-338.
42. MASUDA N, MATSUI K, NEGORO S et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. (1998) 16(10):3329-3334.
43. AGELAKI S, SYRIGOS K, CHRISTOPHYLAKIS C et al.: A multicenter phase II study of the combination ofirinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology (2004) 66(3):192-196.
44. SCHUETTE W, NAGEL S, JUERGENS S et al.: Phase II trial of gemcitabine/Irinotecan in refractory or relapsed small-cell lung cancer. Clin. Lung Cancer (2005) 7(2):133-137.
45. ICHIKI M, GOHARA R, RIKIMARU T et al.: Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy (2003) 49(4):200-205.
46. RUSHING DA: Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC. Oncology (Huntingt) (2000) 14(7 Suppl. 5):63-66.
47. SEKINE I, NISHIWAKI Y, KAKINUMA R et al.: Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br. J. Cancer (2003) 88(6):808-813.
48. GOTO K, SEKINE I, NISHIWAKI Y et al.: Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br. J. Cancer (2004) 91(4):659-665.
49. FUJITA A, TAKABATAKE H, TAGAKI S, SEKINE K: Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology (2000) 59(2):105-109.
50. PIGNON JP, ARRIAGADA R, IHDE D et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. (1992) 327:1618-1624.
51. WARDE P, PAYNE D: Does thoracic irradiation improve survival and local control in limited- stage small-cell carcinoma of the lung? J. Clin. Oncol. (1992) 10:890-895.
52. MURRAY N: Treatment of small cell lung cancer: the state of the art. Lung Cancer (1997) 17(Suppl 1):S75-S89.
53. TURRISI AT, KIM K, BLUM R et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. (1999) 340:265-271.
54. TAMURA K, TAKADA M, KAWASE I et al.: Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn. J. Cancer Res. (1997) 88(2):218-223.
55. KASHII T, SAITO H, NEGORO S et al.: Phase II study of cisplatin plus etoposide with concurrent thoracic radiotherapy (TRT) followed by irintoecan plus cisplatin in limited stage small-cell lung cancer (SCLC); A West Japan Thoracic Oncology Group Trial. Lung Cancer (2005) 49(Suppl. 2):S322.
56. HAN JY, CHO KH, LEE DH et al.: Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J. Clin. Oncol. (2005) 23(15):3488-3494.
57. RAEFSKY EL, SPIGEL DR, GRECO FA et al.: Irinotecan (1), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2005) 23:633s.
58. SOHN J, MOON Y, LEE C et al.: Phase II trial of irinotecan and cisplatin with concurrent radiotherapy in limited-disease small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:662s.
59. LANGER C, SWANN S, WERNER-WASIK M et al.: Phase I study of combination irinotecan and cisplatin and either twice daily thoracic radiation (45Gy) or once daily thoracic radiotherapy (7OGy) in patients with limited small cell lung carcinoma (SCLC): Early toxicity analysis of RTOG 0241. Lung Cancer (2005) 49(Suppl. 2):S323.
60. MCLEOD HL, WATTERS JW: Irinotecan pharmacogenetics: is it time to intervene? J. Clin. Oncol. (2004) 22(8):1356-1359.